Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Blood (2022) 139 (25): 3605–3616.

https://doi.org/10.1182/blood.2022015423

Published: 2022

Includes: Supplemental data

Journal Articles

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Craig H. Moskowitz, Jan Walewski, Auayporn Nademanee, Tamas Masszi, Edward Agura, Jerzy Holowiecki, Muneer H. Abidi, Andy I. Chen, Patrick Stiff, Simonetta Viviani, Veronika Bachanova, Anna Sureda, Teresa McClendon, Connie Lee, Julie Lisano, John Sweetenham

Blood (2018) 132 (25): 2639–2642.

https://doi.org/10.1182/blood-2018-07-861641

Published: 2018

Journal Articles

High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender

Zheng Zhou, MD PhD, Alfred W. Rademaker, PhD, Leo I. Gordon, MD, Ann S. LaCasce, MD, Allison Crosby-Thompson, Ann Vanderplas, MS, Gregory A Abel, MD MPH, Maria A. Rodriguez, MD, Auayporn Nademanee, MD, Mark Kaminski, Myron S. Czuczman, MD, Michael M. Millenson, MD, Joyce Niland, PhD, Andrew D. Zelenetz, MD PhD, Jonathan W. Friedberg, MD, Jane N. Winter, MD

Blood (2014) 124 (21): 3046.

https://doi.org/10.1182/blood.V124.21.3046.3046

Published: 2014

Journal Articles

Do Changes in Transplant Practice Influence Risk of Therapy-Related Myelodysplasia/ Acute Myeloid Leukemia after Autologous Hematopoietic Cell Transplantation (aHCT) for Non-Hodgkin Lymphoma (NHL)?

Can-Lan Sun, Jennifer Berano-Teh, Patrick Halliday, Lindsey Hageman, Maya Ramamurthy, Saro Armenian, Alicia Gonzales, Liezl Atencio, Liton Francisco, F. Lennie Wong, Auayporn Nademanee, MD, Robert W Chen, MD, Margaret O'Donnell, Joseph Rosenthal, Leslie L. Popplewell, MD, Shirong Wang, Stephen J. Forman, Ravi Bhatia, Smita Bhatia, PhD

Blood (2014) 124 (21): 430.

https://doi.org/10.1182/blood.V124.21.430.430

Published: 2014

Journal Articles

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Zheng Zhou, Laurie H. Sehn, Alfred W. Rademaker, Leo I. Gordon, Ann S. LaCasce, Allison Crosby-Thompson, Ann Vanderplas, Andrew D. Zelenetz, Gregory A. Abel, Maria A. Rodriguez, Auayporn Nademanee, Mark S. Kaminski, Myron S. Czuczman, Michael Millenson, Joyce Niland, Randy D. Gascoyne, Joseph M. Connors, Jonathan W. Friedberg, Jane N. Winter

Blood (2014) 123 (6): 837–842.

https://doi.org/10.1182/blood-2013-09-524108

Published: 2014

Includes: Supplemental data

Journal Articles

Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma

Robert Chen, MD, Paul Frankel, PhD, Leslie Popplewell, MD, Tanya Siddiqi, MD, Wei Ye, Joel Conrad, BS, Michelle Mott, RN, Auayporn Nademanee, MD, Myo Htut, MD, Stephen J. Forman, MD, Mark Kirschbaum, MD

Blood (2013) 122 (21): 4398.

https://doi.org/10.1182/blood.V122.21.4398.4398

Published: 2013

Journal Articles

Brentuximab Vedotin Improves HCT-CI, CR Status, and Peri-Transplant Toxicity In Patients With Relapsed/Refractory Hodgkin Lymphoma Heading To RIC Allo-HCT

Robert Chen, MD, Joycelynne Palmer, PhD, Ni-Chun Tsai, MS MPH, Sandra H. Thomas, PhD, Tanya Paris, Leslie Popplewell, MD, Chatchada Karanes, MD, Tanya Siddiqi, MD, Auayporn Nademanee, MD, Ji-Lian Cai, MD, Stephen J. Forman, MD

Blood (2013) 122 (21): 3374.

https://doi.org/10.1182/blood.V122.21.3374.3374

Published: 2013

Journal Articles

Immunologic and Clinical Responses To a CD20-Targeted Immunocytokine, DI-Leu16-IL2, In Relapsed Non-Hodgkin Lymphoma

Ryotaro Nakamura, Robert Chen, MD, Joycelynne Palmer, PhD, Karl Gaal, MD, Auayporn Nademanee, MD, Leslie Popplewell, MD, James E. Talmadge, PhD, Stephen Gillies, PhD, David Colcher, PhD, Stephen J. Forman, MD, Andrew Raubitschek, MD

Blood (2013) 122 (21): 1808.

https://doi.org/10.1182/blood.V122.21.1808.1808

Published: 2013

Journal Articles

An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.

Zheng Zhou, MD, PhD, Alfred W. Rademaker, PhD, Leo I. Gordon, MD, Ann S. LaCasce, MD, Ann Vanderplas, MS, Allison Crosby-Thompson, Andrew D Zelenetz, MD, PhD, Gregory A. Abel, MD, MPH, Maria A. Rodriguez, MD, Auayporn Nademanee, MD, Mark S. Kaminski, MD, Myron S. Czuczman, MD, Michael Millenson, MD, Joyce Niland, PhD, Jonathan W. Friedberg, MD, Jane N. Winter, MD

Blood (2012) 120 (21): 2656.

https://doi.org/10.1182/blood.V120.21.2656.2656

Published: 2012

Journal Articles

Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database.

Makiko Ban-Hoefen, MD, Ann Vanderplas, MS, Jennifer L. Kelly, PhD, MPH, Allison Crosby-Thompson, Gregory A. Abel, MD, MPH, Myron S. Czuczman, MD, Leo I. Gordon, MD, Mark S. Kaminski, MD, Michael Millenson, MD, Auayporn Nademanee, MD, Maria A. Rodriguez, MD, Andrew D. Zelenetz, MD, PhD, Joyce Niland, PhD, Ann LaCasce, MD, Jonathan W. Friedberg, MD

Blood (2012) 120 (21): 2669.

https://doi.org/10.1182/blood.V120.21.2669.2669

Published: 2012

Journal Articles

Comparison of Referring and Final Pathology for T-Cell Lymphomas in the NCCN

Alex F Herrera, MD, Allison Crosby-Thompson, Jonathan W. Friedberg, MD, Gregory A. Abel, MD, MPH, Myron S. Czuczman, MD, Leo I. Gordon, MD, Mark S. Kaminski, MD, Michael Millenson, MD, Auayporn Nademanee, MD, Joyce Niland, PhD, Maria A. Rodriguez, MD, Andrew D. Zelenetz, MD, PhD, Ann S. LaCasce, MD

Blood (2012) 120 (21): 1610.

https://doi.org/10.1182/blood.V120.21.1610.1610

Published: 2012

Journal Articles

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Robert W. Chen, MD, Leslie Popplewell, MD, Paul Frankel, PhD, Tanya Siddiqi, MD, Joel Conrad, BS, Michelle Mott, RN, Myo Htut, MD, Auayporn Nademanee, MD, Stephen J Forman, MD, Mark Kirschbaum, MD

Blood (2012) 120 (21): 3698.

https://doi.org/10.1182/blood.V120.21.3698.3698

Published: 2012

Journal Articles

The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation

Frederick L Locke, MD, Joseph Pidala, MD, MS, Barry Storer, PhD, Paul J. Martin, MD, Michael A Pulsipher, MD, Thomas Chauncey, MD, PhD, Niels Jacobsen, MD, DMSC, Nikolaus Kroeger, MD, Irwin Walker, MBBS, Mary C Territo, Susan Light, MD, Ginna G Laport, MD, Auayporn Nademanee, MD, Raymond Powles, MD, Armand Keating, MD, Gerard Socie, MD, Claudio Anasetti, MD

Blood (2012) 120 (21): 4195.

https://doi.org/10.1182/blood.V120.21.4195.4195

Published: 2012

Journal Articles

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma

Robert Chen, Joycelynne M. Palmer, Sandra H. Thomas, Ni-Chun Tsai, Len Farol, Auayporn Nademanee, Stephen J. Forman, Ajay K. Gopal

Blood (2012) 119 (26): 6379–6381.

https://doi.org/10.1182/blood-2012-03-418673

Published: 2012

Journal Articles

Outcomes with Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Relapsed/Refractory Follicular Lymphoma (FL) in the Post-Rituximab Era: A Comparative Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma (NHL) Outcomes Database Project,

Andrew M. Evens, DO, MSc, Ann Vanderplas, M.S., Ann LaCasce, MD, MSc, Allison Crosby, MS, Auayporn Nademanee, M.D., Mark S. Kaminski, MD, Gregory A. Abel, MD, MPH, Michael Millenson, MD, Myron S. Czuczman, MD, Maria A. Rodriguez, MD, Joyce Niland, PhD, Andrew D Zelenetz, MD, PhD, Leo I. Gordon, MD, FACP, Jonathan Friedberg, MD

Blood (2011) 118 (21): 4112.

https://doi.org/10.1182/blood.V118.21.4112.4112

Published: 2011

Journal Articles

Cause-Specific Conditional Survival In 2603 Consecutive Patients Undergoing Autologous Hematopoietic Cell Transplantation (aHCT) Over a 20-Year Period

Ari M. Vander Walde, M.D., M.P.H., Can-Lan Sun, Ph.D., Liton Francisco, B.S., Saro Armenian, D.O., M.P.H., Jennifer Berano Teh, M.D., F. Lennie Wong, Ph.D., Neal Kogut, M.D., Amrita Krishnan, M.D., Auayporn Nademanee, M.D., Leslie Popplewell, M.D., Anthony Selwyn Stein, M.D., Stephen J. Forman, M.D., Smita Bhatia

Blood (2010) 116 (21): 933.

https://doi.org/10.1182/blood.V116.21.933.933

Published: 2010

Journal Articles

Early Mortality After Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies Performed In the Recent Era

Lester A. Laddaran, B.A., Can-Lan Sun, Ph.D., Ari M. VanderWalde, MD, MPH, Liton Francisco, B.S., Saro Armenian, D.O., M.P.H., Jennifer Berano Teh, M.D., F. Lennie Wong, Ph.D., Chatchada Karanes, MD, Neil Martin Kogut, MD, Amrita Krishnan, M.D., Auayporn Nademanee, M.D., Margaret O'Donnell, M.D., F.R.C.P.C., Pablo Parker, M.D., Leslie Popplewell, M.D., Anthony Selwyn Stein, M.D., Stephen J. Forman, M.D., Smita Bhatia

Blood (2010) 116 (21): 902.

https://doi.org/10.1182/blood.V116.21.902.902

Published: 2010

Journal Articles

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Mark Kirschbaum, MD, Leslie Popplewell, M.D., Maria L Delioukina, MD, Robert w Chen, Vinod Pullarkat, Paul Frankel, Joel Conrad, Joyce Hartshorn, Auayporn Nademanee, M.D., Stephen Forman, MD

Blood (2010) 116 (21): 3957.

https://doi.org/10.1182/blood.V116.21.3957.3957

Published: 2010

Journal Articles

Comparative Analysis of Autologous Hematopoietic Cell Transplantation with Radioimmunotherapy (RIT) Based Conditioning Versus Total Body Irradiation (TBI) for High-Risk Diffuse Large Cell Lymphoma (DLCL): Toxicity and Efficacy

Amrita Krishnan, M.D., Joycelynne Palmer, PhD, Auayporn Nademanee, M.D., Andrew Raubitschek, MD, Dave Yamauchi, Neil Martin Kogut, MD, Laura Federico, Nicole Tsai, Stephen Forman, M.D.

Blood (2010) 116 (21): 32.

https://doi.org/10.1182/blood.V116.21.32.32

Published: 2010

Journal Articles

Incidence, Method and Covariates of Central Nervous System (CNS) Prophylaxis for Diffuse Large B-Cell Lymphoma In the National Comprehensive Cancer Network (NCCN) Lymphoma Database

Anita Kumar, MD, Ann Vanderplas, Ann S. LaCasce, MD, MSc, Maria A. Rodriguez, MD, Allison L. Crosby, MS, Eva Lepisto, MSc, MA, Myron S. Czuczman, MD, Auayporn Nademanee, M.D., Joyce Niland, PhD, Leo I. Gordon, MD, FACP, Michael Millenson, MD, Andrew D. Zelenetz, MD, PhD, Jonathan W. Friedberg, MD, Gregory A. Abel, MD, MPH

Blood (2010) 116 (21): 1756.

https://doi.org/10.1182/blood.V116.21.1756.1756

Published: 2010

NARROW

Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender

Do Changes in Transplant Practice Influence Risk of Therapy-Related Myelodysplasia/ Acute Myeloid Leukemia after Autologous Hematopoietic Cell Transplantation (aHCT) for Non-Hodgkin Lymphoma (NHL)?

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma

Brentuximab Vedotin Improves HCT-CI, CR Status, and Peri-Transplant Toxicity In Patients With Relapsed/Refractory Hodgkin Lymphoma Heading To RIC Allo-HCT

Immunologic and Clinical Responses To a CD20-Targeted Immunocytokine, DI-Leu16-IL2, In Relapsed Non-Hodgkin Lymphoma

An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.

Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database.

Comparison of Referring and Final Pathology for T-Cell Lymphomas in the NCCN

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma

Outcomes with Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Relapsed/Refractory Follicular Lymphoma (FL) in the Post-Rituximab Era: A Comparative Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma (NHL) Outcomes Database Project,

Cause-Specific Conditional Survival In 2603 Consecutive Patients Undergoing Autologous Hematopoietic Cell Transplantation (aHCT) Over a 20-Year Period

Early Mortality After Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies Performed In the Recent Era

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Comparative Analysis of Autologous Hematopoietic Cell Transplantation with Radioimmunotherapy (RIT) Based Conditioning Versus Total Body Irradiation (TBI) for High-Risk Diffuse Large Cell Lymphoma (DLCL): Toxicity and Efficacy

Incidence, Method and Covariates of Central Nervous System (CNS) Prophylaxis for Diffuse Large B-Cell Lymphoma In the National Comprehensive Cancer Network (NCCN) Lymphoma Database

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only